Market Closed -
Bombay S.E.
03:00:42 2024-05-18 am EDT
|
5-day change
|
1st Jan Change
|
323.7
INR
|
+1.84%
|
|
+0.40%
|
-10.02%
|
Fiscal Period: March |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
645.1
|
405.1
|
204.7
|
670.3
|
4,321
|
2,755
|
Enterprise Value (EV)
1 |
637.8
|
467.7
|
272
|
767.7
|
4,785
|
3,656
|
P/E ratio
|
58.1
x
|
21.2
x
|
23.9
x
|
9.7
x
|
23.3
x
|
19.8
x
|
Yield
|
0.97%
|
1.54%
|
1.83%
|
0.93%
|
0.22%
|
0.25%
|
Capitalization / Revenue
|
1.18
x
|
0.68
x
|
0.33
x
|
0.84
x
|
3.2
x
|
1.6
x
|
EV / Revenue
|
1.16
x
|
0.78
x
|
0.44
x
|
0.97
x
|
3.54
x
|
2.12
x
|
EV / EBITDA
|
11.8
x
|
9.55
x
|
5.69
x
|
7.13
x
|
19
x
|
10.8
x
|
EV / FCF
|
18.8
x
|
-8.93
x
|
32.8
x
|
-11.4
x
|
-10.4
x
|
-3.92
x
|
FCF Yield
|
5.31%
|
-11.2%
|
3.05%
|
-8.78%
|
-9.63%
|
-25.5%
|
Price to Book
|
1.19
x
|
0.73
x
|
0.37
x
|
1.08
x
|
3.91
x
|
2.95
x
|
Nbr of stocks (in thousands)
|
6,233
|
6,233
|
6,233
|
6,233
|
9,349
|
7,012
|
Reference price
2 |
103.5
|
65.00
|
32.85
|
107.6
|
462.2
|
393.0
|
Announcement Date
|
8/23/18
|
7/26/19
|
7/20/20
|
6/21/21
|
8/26/22
|
7/4/23
|
Fiscal Period: March |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
547.6
|
597.8
|
615.5
|
795.1
|
1,351
|
1,724
|
EBITDA
1 |
54.25
|
48.96
|
47.79
|
107.7
|
251.3
|
337.7
|
EBIT
1 |
10.93
|
16.98
|
11.85
|
69.9
|
201.3
|
267.8
|
Operating Margin
|
2%
|
2.84%
|
1.92%
|
8.79%
|
14.9%
|
15.54%
|
Earnings before Tax (EBT)
1 |
16.82
|
20.69
|
13.71
|
91.55
|
193.9
|
249.9
|
Net income
1 |
11.11
|
19.2
|
8.575
|
69.12
|
139.1
|
184.5
|
Net margin
|
2.03%
|
3.21%
|
1.39%
|
8.69%
|
10.3%
|
10.7%
|
EPS
2 |
1.780
|
3.070
|
1.376
|
11.09
|
19.84
|
19.89
|
Free Cash Flow
1 |
33.84
|
-52.39
|
8.298
|
-67.38
|
-460.7
|
-933
|
FCF margin
|
6.18%
|
-8.76%
|
1.35%
|
-8.47%
|
-34.11%
|
-54.13%
|
FCF Conversion (EBITDA)
|
62.38%
|
-
|
17.36%
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
304.59%
|
-
|
96.77%
|
-
|
-
|
-
|
Dividend per Share
2 |
1.000
|
1.000
|
0.6000
|
1.000
|
1.000
|
1.000
|
Announcement Date
|
8/23/18
|
7/26/19
|
7/20/20
|
6/21/21
|
8/26/22
|
7/4/23
|
Fiscal Period: March |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
-
|
62.6
|
67.3
|
97.4
|
464
|
900
|
Net Cash position
1 |
7.33
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
1.279
x
|
1.408
x
|
0.904
x
|
1.845
x
|
2.666
x
|
Free Cash Flow
1 |
33.8
|
-52.4
|
8.3
|
-67.4
|
-461
|
-933
|
ROE (net income / shareholders' equity)
|
2.05%
|
3.5%
|
1.54%
|
11.7%
|
19.2%
|
16%
|
ROA (Net income/ Total Assets)
|
0.96%
|
1.46%
|
1%
|
5.09%
|
9.63%
|
7.39%
|
Assets
1 |
1,158
|
1,315
|
856.2
|
1,359
|
1,445
|
2,496
|
Book Value Per Share
2 |
87.20
|
89.00
|
89.20
|
99.60
|
118.0
|
133.0
|
Cash Flow per Share
2 |
1.180
|
0.0900
|
0.5300
|
0.1600
|
1.990
|
1.600
|
Capex
1 |
10.5
|
71.1
|
53
|
235
|
443
|
1,059
|
Capex / Sales
|
1.92%
|
11.89%
|
8.61%
|
29.52%
|
32.82%
|
61.43%
|
Announcement Date
|
8/23/18
|
7/26/19
|
7/20/20
|
6/21/21
|
8/26/22
|
7/4/23
|
|
1st Jan change
|
Capi.
|
---|
| -10.02% | 35.34M | | +32.09% | 693B | | +29.39% | 584B | | -1.34% | 372B | | +20.34% | 332B | | +7.39% | 294B | | +14.25% | 239B | | -3.03% | 211B | | +10.02% | 210B | | +8.49% | 168B |
Other Pharmaceuticals
|